ClinicalTrials.gg
CompletedNCT03569293Measure Up 1Updated Jun 17, 2026Results posted

Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

A Phase 3 interventional study of Placebo for Upadacitinib and Upadacitinib in Atopic Dermatitis, sponsored by AbbVie. Completed at 180 sites in 25 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
912
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing upadacitinib in Dermatitis, Atopic — 2 open to participants now, 6 under way, 4 of them phase 3. upadacitinib · Dermatitis, Atopic.

Enrollment
3rd of 17
912 · median 272
Started
2018
with 3 others
Phase 3
12 of 17
none open now
Registered
2nd of 17
by date
Lead sponsor
15 of 17
AbbVie

Among the 17 studies testing upadacitinib in Dermatitis, Atopic, this one is the 3rd largest by enrollment, is one of 4 that started in 2018, is one of 12 in phase 3, and was the 2nd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 17 studies testing upadacitinib in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing upadacitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

Read the detailed description

This study includes a 35-day screening period, a 16-week double-blind period, a blinded extension period up to Week 260, and a 30-day follow-up visit.

Participants who meet eligibility criteria in the main study will be randomized in a 1:1:1 ratio to receive a daily oral dose of upadacitinib 30 mg or upadacitinib 15 mg or matching placebo. Upon completion of enrollment of 810 participants in the main study, a supplemental study will continue to enroll adolescents (adolescent sub-study) until a total of 180 adolescent participants are enrolled in the overall study (main study + adolescent sub-study).

Randomization for the main study will be stratified by baseline disease severity (validated Investigator Global Assessment scale for Atopic Dermatitis [vIGA-AD] score of moderate [3] versus severe [4]), by geographic region (United States [US]/Puerto Rico/Canada, Japan, China, and Other), and by age (adolescent [ages 12 to 17] versus adult [ages 18 to 75]). The separate randomization for the adolescent sub-study will be stratified by baseline disease severity (moderate [vIGA-AD 3] vs. severe [vIGA-AD 4]) and by geographic region (US/Puerto Rico/Canada and Other).

At Week 16 of the main study and the adolescent sub-study, participants in the placebo group will be re-randomized in a 1:1 ratio to receive daily oral doses of upadacitinib 30 mg or upadacitinib 15 mg in the blinded extension period. In the main study the re-randomization at Week 16 will be stratified by Week 16 50% improvement in Eczema Area and Severity Index [EASI 50] responder [yes/no], geographic region [US/Puerto Rico/Canada, China [Mainland], Japan, and other], and age group [adolescent/adult]. For the adolescent sub-study, the re-randomization will be stratified by EASI 50 responder (Yes/No) and by geographic region (US/Puerto Rico/Canada and Other).

Participants originally randomized to upadacitinib will continue upadacitinib in the extension period at the same dose.

Starting at the Week 4 visit, rescue treatment for AD may be provided at the discretion of the investigator if medically necessary.

The Primary Analysis for the main study will be conducted after all ongoing participants have completed Week 16. In addition, a Primary Analysis for the adolescent population (including the adolescent participants from the main study and the adolescent sub-study) will be conducted after all ongoing adolescent participants have completed Week 16.

Following the interim analysis, significant noncompliance was identified at a clinical site. As a result, all data from the site, including data from 10 adolescent participants, has been excluded from the final analysis of the outcome measures as appropriate.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Atopic Dermatitis
  • Upadacitinib
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight of ≥ 40 kg at Baseline Visit for participants between ≥ 12 and \< 18 years of age
  • Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years before Baseline Visit and subject meets Hanifin and Rajka criteria.
  • Active moderate to severe AD defined by:

    • Eczema Area and Severity Index (EASI) score ≥ 16 at the Screening and Baseline Visits;
    • Validated Investigator's Global Assessment (vIGA) score ≥ 3 at the Screening and Baseline Visits;
    • ≥ 10% Body surface area (BSA) of AD involvement at the Screening and Baseline Visits;
    • Baseline weekly average of daily Worst Pruritus NRS ≥ 4.
  • Candidate for systemic therapy or have recently required systemic therapy for AD
  • Subject has applied a topical emollient (moisturizer) twice daily for at least 7 days before the Baseline Visit.
  • Documented history of inadequate response to topical (TCS) or topical calcineurin inhibitor (TCI) or documented systemic treatment for AD within 6 months before Baseline Visit

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to any Janus kinase (JAK) inhibitor
  • Unable or unwilling to discontinue current atopic dermatitis treatments prior to the study
  • Requirement of prohibited medications during the study
  • Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions
  • Female subject who is pregnant, breastfeeding, or considering pregnancy during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
912 participants (actual)

Study arms

  • Placebo comparator
    Placebo / Upadacitinib

    Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260.

    Drug: Placebo for Upadacitinib · Drug: Upadacitinib

  • Experimental
    Upadacitinib 15 mg QD

    Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks.

    Drug: Upadacitinib

  • Experimental
    Upadacitinib 30 mg QD

    Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks.

    Drug: Upadacitinib

Interventions

  • DrugPlacebo for Upadacitinib

    Tablets taken orally once a day

  • Tablets taken orally once a day

    Also known as: ABT-494, RINVOQ™

06

What researchers measure

Primary outcomes

  1. Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    Time frame: Baseline and Week 16

  2. Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16

    The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No inflammatory signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  2. Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    Time frame: Baseline and Week 16

  3. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 4

  4. Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 2

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Week 2

  5. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 1

  6. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percentage of participants who had a 4-point or greater improvement from Baseline in Worst Pruritus NRS score at Day 2 was pre-specified as a ranked secondary endpoint for participants in the upadacitinib 30 mg group versus placebo group only.

    Time frame: Baseline and Day 2

  7. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percentage of participants who had a 4-point or greater improvement in Worst Pruritus NRS score from Baseline at Day 3 was pre-specified as a ranked secondary endpoint for participants in the upadacitinib 15 mg group versus placebo group only.

    Time frame: Baseline and Day 3

  8. Main Study: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period

    A flare, characterized as a clinically meaningful worsening in EASI, is defined as an increase in EASI score of ≥ 6.6 points from Baseline during the double-blind treatment period and prior to use of any rescue medication. Flare was assessed in participants with an EASI score of 65.4 or less at Baseline.

    Time frame: From first dose of study drug to Week 16

  9. Main Study: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in Atopic Dermatitis Impact Scale (ADerm-IS) Sleep Domain Score at Week 16

    The ADerm-IS is a 10-item patient reported outcome (PRO) questionnaire designed to assess a variety of impacts that participants experience from their AD. The ADerm-IS sleep domain consists of 3 questions designed to assess the impact of AD on sleep on a daily basis over a 24-hour recall period. The items include difficulty falling asleep, impact on sleep, and waking at night. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The ADerm-IS sleep domain score is the sum of the 3 item scores and ranges from 0 (no impact) to 30 (worst impact). The ADerm-IS sleep domain was analyzed based on weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-IS sleep domain score is 12.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  10. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Atopic Dermatitis Symptom Scale (ADerm-SS) Skin Pain Score at Week 16

    The ADerm-SS is an 11-item PRO questionnaire designed to assess signs and symptoms that patients may experience due to AD using a 24-hour recall period. For the skin pain item participants were asked on a daily basis to indicate how bad their worst skin pain due to AD was in the past 24 hours on an NRS from 0 (no pain) to 10 (worst imaginable pain). The ADerm-SS skin pain score was analyzed using weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-SS skin pain score is 4.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  11. Main Study: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS 7-Item Total Symptom Score (TSS-7) at Week 16

    The ADerm-SS is an 11-item questionnaire designed to assess signs and symptoms that participants may experience due to AD using a 24-hour recall period. The 7-item total symptom score includes 7 symptoms (items 1-7 of the ADerm-SS), each assessed on a NRS from 0 (no symptom) to 10 (worst imaginable). The 7 symptoms included in the score are itch while asleep, itch while awake, skin pain (each assessed daily), skin cracking, skin cracking pain, dry skin, and skin flaking (assessed weekly). The TSS-7 score ranges from 0 to 70, with higher scores indicating worsening symptoms. The minimal clinically important difference for ADerm-SS TSS-7 is 28.

    Time frame: Baseline and Week 16

  12. Main Study: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16

    The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS emotional state sums three items \[Items 8-10\] measuring self-consciousness, embarrassment, and sadness with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The emotional state domain score ranges from 0 to 30, where higher scores represent worst impact. The minimal clinically important difference for ADerm-IS emotional state domain score is 11.

    Time frame: Baseline and Week 16

  13. Main Study: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in in ADerm-IS Daily Activities Domain Score at Week 16

    The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS daily activities sums four items measuring limitations of household, physical, and social activities, and difficulty concentrating with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The daily activities domain score ranges from 0 to 40, where higher scores represent worst impact. The minimal clinically important difference for the ADerm-IS daily activities domain score is 14.

    Time frame: Baseline and Week 16

  14. Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    Time frame: Baseline and Week 16

  15. Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  16. Main Study: Percent Change From Baseline in EASI Score at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 16

  17. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Week 16

    The POEM is a 7-item, validated questionnaire used to assess disease symptoms in both children and adults. Participants respond to 7 questions, including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping, each scored on a 5-point scale based on frequency of occurrence during the previous week: 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days. Item scores are added to provide a total score ranging from 0 (clear) to 28 (very severe atopic eczema). A change in POEM score of 3.4 points is considered the minimal clinically important difference.

    Time frame: Baseline and Week 16

  18. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Dermatology Life Quality Index (DLQI) at Week 16

    The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.

    Time frame: Baseline and Week 16

  19. Main Study: Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 16

    SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 16

  20. Main Study: Percentage of Participants Achieving a Hospital Anxiety and Depression Scale-Anxiety (HADS-A) Score and Hospital Anxiety and Depression Scale-Depression (HADS-D) Score of < 8 at Week 16

    The HADS is a 14-item questionnaire, with seven items related to anxiety (HADS-A) and seven items related to depression (HADS-D). Each item is scored from 0 to 3; scores for each subscale range from 0 to 21, with higher scores indicating more distress. For each domain, scores 7 or lower are considered normal, 8 to 10 are borderline, and 11 or higher indicate clinical anxiety or depression.

    Time frame: Baseline and Week 16

  21. Main Study: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16

    The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.

    Time frame: Week 16

  22. Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Week 16

  23. Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16

    The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.

    Time frame: Baseline and Week 16

  24. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  25. Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Week 16

  26. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 4

  27. Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Week 2

  28. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 1

  29. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

    Time frame: Baseline and Day 2

  30. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

    Time frame: Baseline and Day 3

  31. Adolescents: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period

    A flare, characterized as a clinically meaningful worsening in EASI, is defined as an increase in EASI score of ≥ 6.6 points from Baseline during the double-blind treatment period and prior to use of any rescue medication. Flares were assessed in participants with an EASI score of 65.4 or less at Baseline.

    Time frame: From first dose of study drug to Week 16

  32. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in ADerm-IS Sleep Domain Score at Week 16

    The ADerm-IS is a 10-item patient reported outcome questionnaire designed to assess a variety of impacts that participants experience from their AD. The ADerm-IS sleep domain consists of 3 questions designed to assess the impact of AD on sleep on a daily basis over a 24-hour recall period. The items include difficulty falling asleep, impact on sleep, and waking at night. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The ADerm-IS sleep domain score is the sum of the 3 item scores and ranges from 0 (no impact) to 30 (worst impact). The ADerm-IS sleep domain was analyzed based on weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-IS sleep domain score is 12.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  33. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in ADerm-SS Skin Pain Score at Week 16

    The ADerm-SS is an 11-item PRO questionnaire designed to assess signs and symptoms that patients may experience due to AD using a 24-hour recall period. For the skin pain item participants were asked to indicate on a daily basis how bad their worst skin pain due to AD was in the past 24 hours on an NRS from 0 (no pain) to 10 (worst imaginable pain). The minimal clinically important difference for ADerm-SS skin pain score is 4. The ADerm-SS skin pain score was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  34. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS TSS-7 at Week 16

    The ADerm-SS is an 11-item questionnaire designed to assess signs and symptoms that participants may experience due to AD using a 24-hour recall period. The 7-item total symptom score includes 7 symptoms (items 1-7 of the ADerm-SS), each assessed on a NRS from 0 (no symptom) to 10 (worst imaginable). The 7 symptoms included in the score are itch while asleep, itch while awake, skin pain (each assessed daily), skin cracking, skin cracking pain, dry skin, and skin flaking (assessed weekly). The TSS-7 score ranges from 0 to 70, with higher scores indicating worsening symptoms. The minimal clinically important difference for ADerm-SS TSS-7 is 28.

    Time frame: Baseline and Week 16

  35. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16

    The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS emotional state sums three items \[Items 8-10\] measuring self-consciousness, embarrassment, and sadness with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The emotional state domain score ranges from 0 to 30, where higher scores represent worst impact. The minimal clinically important difference for ADerm-IS emotional state domain score is 11.

    Time frame: Baseline and Week 16

  36. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in ADerm-IS Daily Activities Domain Score at Week 16

    The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS daily activities sums four items measuring limitations of household, physical, and social activities, and difficulty concentrating with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The daily activities domain score ranges from 0 to 40, where higher scores represent worst impact. The minimal clinically important difference for the ADerm-IS daily activities domain score is 14.

    Time frame: Baseline and Week 16

  37. Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 100 response is defined as a 100% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Week 16

  38. Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  39. Adolescents: Percent Change From Baseline in EASI Score at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 16

  40. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in POEM Total Score at Week 16

    The POEM is a 7-item, validated questionnaire used to assess disease symptoms in both children and adults. Participants respond to 7 questions, including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping, each scored on a 5-point scale based on frequency of occurrence during the previous week: 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days. Item scores are added to provide a total score ranging from 0 (clear) to 28 (very severe atopic eczema). A change in POEM score of 3.4 points is considered the minimal clinically important difference.

    Time frame: Baseline and Week 16

  41. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in DLQI Score at Week 16

    The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.

    Time frame: Baseline and Week 16

  42. Adolescents: Percent Change From Baseline in SCORAD Score at Week 16

    SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 16

  43. Adolescents: Percentage of Participants Achieving HADS-A Score and HADS-D Score of < 8 at Week 16

    The HADS is a 14-item questionnaire, with seven items related to anxiety (HADS-A) and seven items related to depression (HADS-D). Each item is scored from 0 to 3; scores for each subscale range from 0 to 21, with higher scores indicating more distress. For each domain, scores 7 or lower are considered normal, 8 to 10 are borderline, and 11 or higher indicate clinical anxiety or depression.

    Time frame: Baseline and Week 16

  44. Adolescents: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16

    The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.

    Time frame: Baseline and Week 16

07

Results

Posted Feb 3, 2022

Participant flow

Participants were enrolled at 151 study sites in 24 countries across Europe, North and South America, Oceania, and the Asia-Pacific region. The study included a 16-week double-blind treatment period followed by a blinded extension period up to Week 260, and a 30-day follow-up visit. The first 810 adults and adolescents enrolled constituted the Main Study; additional adolescents were enrolled in the Adolescent Substudy to ensure enrollment of a total of 180 adolescent participants overall.

Double-blind Period
Participant flow — Double-blind Period
MilestoneAdults: Double-blind Period - PlaceboAdults: Double-blind Period - Upadacitinib 15 mg QDAdults: Double-blind Period - Upadacitinib 30 mg QDAdolescents: Double-blind Period - PlaceboAdolescents: Double-blind Period - Upadacitinib 15 mg QDAdolescents: Double-blind Period - Upadacitinib 30 mg QDAdults: Blinded Extension Period - PBO/Upadacitinib 15 mgAdults: Blinded Extension Period - PBO/Upadacitinib 30 mgAdults: Blinded Extension Period - Upadacitinib 15 mgAdults: Blinded Extension Period - Upadacitinib 30 mgAdolescents: Blinded Extension Period - PBO/Upadacitinib 15 mgAdolescents: Blinded Extension Period - PBO/Upadacitinib 30 mgAdolescents: Blinded Extension Period - Upadacitinib 15 mgAdolescents: Blinded Extension Period - Upadacitinib 30 mg
Started24123924361646400000000
Received study drug in double-blind period24123924361646400000000
Updated itt adolescent (itt a) population00058635800000000
Completed20923123157646400000000
Not completed3281240000000000
Withdrew: Adverse event41410000000000
Withdrew: Withdrawal by subject182520000000000
Withdrew: Lost to follow-up13210000000000
Withdrew: Other92100000000000
Blinded Extension Period
Participant flow — Blinded Extension Period
MilestoneAdults: Double-blind Period - PlaceboAdults: Double-blind Period - Upadacitinib 15 mg QDAdults: Double-blind Period - Upadacitinib 30 mg QDAdolescents: Double-blind Period - PlaceboAdolescents: Double-blind Period - Upadacitinib 15 mg QDAdolescents: Double-blind Period - Upadacitinib 30 mg QDAdults: Blinded Extension Period - PBO/Upadacitinib 15 mgAdults: Blinded Extension Period - PBO/Upadacitinib 30 mgAdults: Blinded Extension Period - Upadacitinib 15 mgAdults: Blinded Extension Period - Upadacitinib 30 mgAdolescents: Blinded Extension Period - PBO/Upadacitinib 15 mgAdolescents: Blinded Extension Period - PBO/Upadacitinib 30 mgAdolescents: Blinded Extension Period - Upadacitinib 15 mgAdolescents: Blinded Extension Period - Upadacitinib 30 mg
Started00000010310523123130276464
Received treatment in the be period00000010210523122830276464
Completed000000576211912022143741
Not completed00000046431121118132723
Withdrew: Adverse event0000006517220240
Withdrew: Withdrawal by subject00000031285759571517
Withdrew: Lost to follow-up0000004417141362
Withdrew: Other0000005621162124

Outcome measures

PrimaryMain Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 1616.3 (12.0 to 20.7)69.6 (64.2 to 75.0)79.7 (75.0 to 84.4)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 63.4 · 95% CI 57.1 to 69.8Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 53.3 · 95% CI 46.4 to 60.2Response Rate Difference = Upadacitinib - Placebo
PrimaryMain Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16

The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No inflammatory signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 168.4 (5.2 to 11.7)48.1 (42.3 to 54.0)62.0 (56.4 to 67.7)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 53.6 · 95% CI 47.2 to 60.0Response rate difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 39.8 · 95% CI 33.2 to 46.4Response rate difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 1611.8 (7.9 to 15.6)52.2 (46.3 to 58.1)60.0 (54.3 to 65.7)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 48.2 · 95% CI 41.3 to 55.0Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 40.5 · 95% CI 33.5 to 47.5Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 168.1 (4.9 to 11.3)53.1 (47.2 to 58.9)65.8 (60.2 to 71.3)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 57.8 · 95% CI 51.5 to 64.1Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 45.1 · 95% CI 38.6 to 51.7Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 4
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 44.4 (2.0 to 6.9)51.5 (45.5 to 57.4)66.8 (61.3 to 72.3)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 62.3 · 95% CI 56.3 to 68.3Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 47.1 · 95% CI 40.7 to 53.4Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving an EASI 75 Response at Week 2

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Week 2
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 2
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 23.6 (1.4 to 5.7)38.1 (32.4 to 43.8)47.4 (41.6 to 53.2)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 43.9 · 95% CI 37.7 to 50.0Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 34.5 · 95% CI 28.6 to 40.5Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 1
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 10.4 (0.0 to 1.1)15.0 (10.7 to 19.2)19.6 (15.0 to 24.3)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 19.2 · 95% CI 14.6 to 23.9Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 14.6 · 95% CI 10.3 to 18.8Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percentage of participants who had a 4-point or greater improvement from Baseline in Worst Pruritus NRS score at Day 2 was pre-specified as a ranked secondary endpoint for participants in the upadacitinib 30 mg group versus placebo group only.

Time frame:
Baseline and Day 2
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 23.7 (1.5 to 6.0)10.5 (6.9 to 14.2)11.8 (8.0 to 15.6)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 8.1 · 95% CI 3.8 to 12.5Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percentage of participants who had a 4-point or greater improvement in Worst Pruritus NRS score from Baseline at Day 3 was pre-specified as a ranked secondary endpoint for participants in the upadacitinib 15 mg group versus placebo group only.

Time frame:
Baseline and Day 3
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 33.3 (1.2 to 5.5)16.4 (12.0 to 20.7)21.1 (16.4 to 25.9)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 13.0 · 95% CI 8.1 to 17.8Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period

A flare, characterized as a clinically meaningful worsening in EASI, is defined as an increase in EASI score of ≥ 6.6 points from Baseline during the double-blind treatment period and prior to use of any rescue medication. Flare was assessed in participants with an EASI score of 65.4 or less at Baseline.

Time frame:
From first dose of study drug to Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period25.2 (20.0 to 30.3)1.1 (0.0 to 2.3)0.0 (NA to NA)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: -25.2 · 95% CI -30.3 to -20.1Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: -24.1 · 95% CI -29.3 to -18.9Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in Atopic Dermatitis Impact Scale (ADerm-IS) Sleep Domain Score at Week 16

The ADerm-IS is a 10-item patient reported outcome (PRO) questionnaire designed to assess a variety of impacts that participants experience from their AD. The ADerm-IS sleep domain consists of 3 questions designed to assess the impact of AD on sleep on a daily basis over a 24-hour recall period. The items include difficulty falling asleep, impact on sleep, and waking at night. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The ADerm-IS sleep domain score is the sum of the 3 item scores and ranges from 0 (no impact) to 30 (worst impact). The ADerm-IS sleep domain was analyzed based on weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-IS sleep domain score is 12.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in Atopic Dermatitis Impact Scale (ADerm-IS) Sleep Domain Score at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in Atopic Dermatitis Impact Scale (ADerm-IS) Sleep Domain Score at Week 1613.2 (8.7 to 17.7)55.0 (48.4 to 61.6)66.1 (59.8 to 72.3)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 52.9 · 95% CI 45.2 to 60.6Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 41.8 · 95% CI 33.9 to 49.7Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Atopic Dermatitis Symptom Scale (ADerm-SS) Skin Pain Score at Week 16

The ADerm-SS is an 11-item PRO questionnaire designed to assess signs and symptoms that patients may experience due to AD using a 24-hour recall period. For the skin pain item participants were asked on a daily basis to indicate how bad their worst skin pain due to AD was in the past 24 hours on an NRS from 0 (no pain) to 10 (worst imaginable pain). The ADerm-SS skin pain score was analyzed using weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-SS skin pain score is 4.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Atopic Dermatitis Symptom Scale (ADerm-SS) Skin Pain Score at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Atopic Dermatitis Symptom Scale (ADerm-SS) Skin Pain Score at Week 1615.0 (10.4 to 19.6)53.6 (47.2 to 59.9)63.5 (57.5 to 69.4)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 48.6 · 95% CI 41.0 to 56.1Response Rate Difference = Upadacitinib - Placebo
  • Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 38.7 · 95% CI 30.9 to 46.5Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS 7-Item Total Symptom Score (TSS-7) at Week 16

The ADerm-SS is an 11-item questionnaire designed to assess signs and symptoms that participants may experience due to AD using a 24-hour recall period. The 7-item total symptom score includes 7 symptoms (items 1-7 of the ADerm-SS), each assessed on a NRS from 0 (no symptom) to 10 (worst imaginable). The 7 symptoms included in the score are itch while asleep, itch while awake, skin pain (each assessed daily), skin cracking, skin cracking pain, dry skin, and skin flaking (assessed weekly). The TSS-7 score ranges from 0 to 70, with higher scores indicating worsening symptoms. The minimal clinically important difference for ADerm-SS TSS-7 is 28.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS 7-Item Total Symptom Score (TSS-7) at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS 7-Item Total Symptom Score (TSS-7) at Week 1615.0 (10.4 to 19.7)53.6 (47.2 to 60.1)67.9 (62.1 to 73.7)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 52.9 · 95% CI 45.4 to 60.3Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 38.3 · 95% CI 30.4 to 46.2Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16

The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS emotional state sums three items \[Items 8-10\] measuring self-consciousness, embarrassment, and sadness with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The emotional state domain score ranges from 0 to 30, where higher scores represent worst impact. The minimal clinically important difference for ADerm-IS emotional state domain score is 11.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 1619.8 (14.4 to 25.2)62.6 (56.3 to 68.9)72.6 (66.7 to 78.4)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 52.5 · 95% CI 44.7 to 60.4Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 42.7 · 95% CI 34.4 to 50.9Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in in ADerm-IS Daily Activities Domain Score at Week 16

The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS daily activities sums four items measuring limitations of household, physical, and social activities, and difficulty concentrating with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The daily activities domain score ranges from 0 to 40, where higher scores represent worst impact. The minimal clinically important difference for the ADerm-IS daily activities domain score is 14.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in in ADerm-IS Daily Activities Domain Score at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in in ADerm-IS Daily Activities Domain Score at Week 1620.3 (14.7 to 25.9)65.0 (58.5 to 71.6)73.2 (67.1 to 79.2)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 53.1 · 95% CI 44.9 to 61.3Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 44.7 · 95% CI 36.2 to 53.2Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 161.8 (0.2 to 3.3)16.7 (12.4 to 21.1)27.0 (21.9 to 32.2)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 25.3 · 95% CI 20.0 to 30.6Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 15.0 · 95% CI 10.4 to 19.6Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Least squares mean · percent change
Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16
percent changePlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16-26.06 (-36.66 to -15.46)-62.79 (-71.60 to -53.99)-72.04 (-80.69 to -63.39)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Least squares (ls) mean difference: -45.98 · 95% CI -58.82 to -33.15Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -36.74 · 95% CI -49.66 to -23.81Difference = Upadacitinib - Placebo
SecondaryMain Study: Percent Change From Baseline in EASI Score at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · percent change
Main Study: Percent Change From Baseline in EASI Score at Week 16
percent changePlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percent Change From Baseline in EASI Score at Week 16-40.71 (-45.18 to -36.23)-80.24 (-83.99 to -76.49)-87.74 (-91.42 to -84.06)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -47.03 · 95% CI -52.37 to -41.70Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -39.53 · 95% CI -44.91 to -34.15Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Week 16

The POEM is a 7-item, validated questionnaire used to assess disease symptoms in both children and adults. Participants respond to 7 questions, including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping, each scored on a 5-point scale based on frequency of occurrence during the previous week: 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days. Item scores are added to provide a total score ranging from 0 (clear) to 28 (very severe atopic eczema). A change in POEM score of 3.4 points is considered the minimal clinically important difference.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Week 1622.8 (17.8 to 27.8)75.0 (69.9 to 80.1)81.4 (76.9 to 86.0)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 58.6 · 95% CI 51.9 to 65.3Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 52.3 · 95% CI 45.2 to 59.4Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Dermatology Life Quality Index (DLQI) at Week 16

The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Dermatology Life Quality Index (DLQI) at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Dermatology Life Quality Index (DLQI) at Week 1629.0 (23.3 to 34.7)75.4 (70.1 to 80.8)82.0 (77.3 to 86.7)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 53.2 · 95% CI 45.9 to 60.5Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 46.7 · 95% CI 39.0 to 54.4Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 16

SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · percent change
Main Study: Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 16
percent changePlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 16-32.68 (-37.26 to -28.11)-65.71 (-69.20 to -62.23)-73.07 (-76.47 to -69.68)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -40.39 · 95% CI -45.75 to -35.03Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -33.03 · 95% CI -38.44 to -27.61Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Hospital Anxiety and Depression Scale-Anxiety (HADS-A) Score and Hospital Anxiety and Depression Scale-Depression (HADS-D) Score of < 8 at Week 16

The HADS is a 14-item questionnaire, with seven items related to anxiety (HADS-A) and seven items related to depression (HADS-D). Each item is scored from 0 to 3; scores for each subscale range from 0 to 21, with higher scores indicating more distress. For each domain, scores 7 or lower are considered normal, 8 to 10 are borderline, and 11 or higher indicate clinical anxiety or depression.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Hospital Anxiety and Depression Scale-Anxiety (HADS-A) Score and Hospital Anxiety and Depression Scale-Depression (HADS-D) Score of < 8 at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Hospital Anxiety and Depression Scale-Anxiety (HADS-A) Score and Hospital Anxiety and Depression Scale-Depression (HADS-D) Score of < 8 at Week 1614.3 (8.2 to 20.4)45.5 (37.4 to 53.6)49.2 (41.0 to 57.4)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 34.9 · 95% CI 24.8 to 45.1Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 31.5 · 95% CI 21.4 to 41.6Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16

The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 164.4 (1.9 to 7.0)30.3 (24.7 to 35.9)41.5 (35.5 to 47.4)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 37.3 · 95% CI 30.8 to 43.8Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 25.9 · 95% CI 19.7 to 32.1Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 1612.1 (3.7 to 20.5)74.6 (63.9 to 85.4)84.5 (75.2 to 93.8)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 72.3 · 95% CI 59.8 to 84.8Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 62.5 · 95% CI 49.0 to 76.1Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16

The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 166.9 (0.4 to 13.4)46.0 (33.7 to 58.3)70.7 (59.0 to 82.4)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 63.4 · 95% CI 50.5 to 76.4Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 39.3 · 95% CI 25.6 to 53.0Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1610.5 (2.6 to 18.5)49.2 (36.6 to 61.7)58.9 (46.0 to 71.8)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 48.6 · 95% CI 33.8 to 63.3Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 38.8 · 95% CI 24.1 to 53.6Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 163.4 (0.0 to 8.1)47.6 (35.3 to 60.0)74.1 (62.9 to 85.4)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 70.5 · 95% CI 58.5 to 82.5Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 44.3 · 95% CI 31.2 to 57.4Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 4
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 43.5 (0.0 to 8.3)49.2 (36.6 to 61.7)64.3 (51.7 to 76.8)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 60.8 · 95% CI 47.4 to 74.2Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 45.7 · 95% CI 32.3 to 59.1Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Week 2
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 23.4 (0.0 to 8.1)39.7 (27.6 to 51.8)55.8 (42.9 to 68.7)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 52.3 · 95% CI 38.6 to 66.0Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 36.3 · 95% CI 23.4 to 49.2Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 1
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 10.0 (NA to NA)9.8 (2.4 to 17.3)23.2 (12.2 to 34.3)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 23.4 · 95% CI 12.4 to 34.4Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = 0.008 · Adjusted response rate difference: 9.7 · 95% CI 2.5 to 16.8Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

Time frame:
Baseline and Day 2
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 21.8 (0.0 to 5.3)14.0 (5.0 to 23.1)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = 0.013 · Adjusted response rate difference: 12.3 · 95% CI 2.6 to 22.0Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

Time frame:
Baseline and Day 3
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 35.4 (0.0 to 11.3)16.9 (7.4 to 26.5)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = 0.042 · Adjusted response rate difference: 11.2 · 95% CI 0.4 to 22.0Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period

A flare, characterized as a clinically meaningful worsening in EASI, is defined as an increase in EASI score of ≥ 6.6 points from Baseline during the double-blind treatment period and prior to use of any rescue medication. Flares were assessed in participants with an EASI score of 65.4 or less at Baseline.

Time frame:
From first dose of study drug to Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period23.2 (12.2 to 34.3)0.0 (NA to NA)0.0 (NA to NA)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: -23.2 · 95% CI -34.3 to -12.2Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: -23.3 · 95% CI -34.3 to -12.2Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in ADerm-IS Sleep Domain Score at Week 16

The ADerm-IS is a 10-item patient reported outcome questionnaire designed to assess a variety of impacts that participants experience from their AD. The ADerm-IS sleep domain consists of 3 questions designed to assess the impact of AD on sleep on a daily basis over a 24-hour recall period. The items include difficulty falling asleep, impact on sleep, and waking at night. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The ADerm-IS sleep domain score is the sum of the 3 item scores and ranges from 0 (no impact) to 30 (worst impact). The ADerm-IS sleep domain was analyzed based on weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-IS sleep domain score is 12.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in ADerm-IS Sleep Domain Score at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in ADerm-IS Sleep Domain Score at Week 1613.3 (3.4 to 23.3)47.9 (33.8 to 62.0)70.7 (56.8 to 84.7)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 57.6 · 95% CI 41.0 to 74.2Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 34.7 · 95% CI 17.6 to 51.8Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in ADerm-SS Skin Pain Score at Week 16

The ADerm-SS is an 11-item PRO questionnaire designed to assess signs and symptoms that patients may experience due to AD using a 24-hour recall period. For the skin pain item participants were asked to indicate on a daily basis how bad their worst skin pain due to AD was in the past 24 hours on an NRS from 0 (no pain) to 10 (worst imaginable pain). The minimal clinically important difference for ADerm-SS skin pain score is 4. The ADerm-SS skin pain score was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in ADerm-SS Skin Pain Score at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in ADerm-SS Skin Pain Score at Week 169.8 (0.7 to 18.8)43.4 (30.1 to 56.7)67.9 (55.4 to 80.5)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 59.3 · 95% CI 44.1 to 74.6Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 32.4 · 95% CI 16.3 to 48.6Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS TSS-7 at Week 16

The ADerm-SS is an 11-item questionnaire designed to assess signs and symptoms that participants may experience due to AD using a 24-hour recall period. The 7-item total symptom score includes 7 symptoms (items 1-7 of the ADerm-SS), each assessed on a NRS from 0 (no symptom) to 10 (worst imaginable). The 7 symptoms included in the score are itch while asleep, itch while awake, skin pain (each assessed daily), skin cracking, skin cracking pain, dry skin, and skin flaking (assessed weekly). The TSS-7 score ranges from 0 to 70, with higher scores indicating worsening symptoms. The minimal clinically important difference for ADerm-SS TSS-7 is 28.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS TSS-7 at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS TSS-7 at Week 1613.0 (3.3 to 22.8)51.0 (37.3 to 64.7)70.0 (57.3 to 82.7)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 57.0 · 95% CI 41.3 to 72.7Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 38.0 · 95% CI 21.4 to 54.7Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16

The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS emotional state sums three items \[Items 8-10\] measuring self-consciousness, embarrassment, and sadness with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The emotional state domain score ranges from 0 to 30, where higher scores represent worst impact. The minimal clinically important difference for ADerm-IS emotional state domain score is 11.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 1620.9 (8.8 to 33.1)60.9 (46.8 to 75.0)78.6 (66.2 to 91.0)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 56.5 · 95% CI 39.0 to 74.0Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 40.1 · 95% CI 21.8 to 58.4Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in ADerm-IS Daily Activities Domain Score at Week 16

The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS daily activities sums four items measuring limitations of household, physical, and social activities, and difficulty concentrating with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The daily activities domain score ranges from 0 to 40, where higher scores represent worst impact. The minimal clinically important difference for the ADerm-IS daily activities domain score is 14.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in ADerm-IS Daily Activities Domain Score at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in ADerm-IS Daily Activities Domain Score at Week 1627.5 (13.7 to 41.3)57.1 (42.2 to 72.1)81.6 (69.3 to 93.9)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 54.1 · 95% CI 35.6 to 72.5Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = 0.004 · Adjusted response rate difference: 29.8 · 95% CI 9.5 to 50.1Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 100 response is defined as a 100% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 160.0 (NA to NA)15.9 (6.8 to 24.9)34.5 (22.3 to 46.7)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 34.4 · 95% CI 22.2 to 46.6Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = 0.001 · Adjusted response rate difference: 15.9 · 95% CI 7.0 to 24.9Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Least squares mean · percent change
Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16
percent changeAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16-24.36 (-35.34 to -13.37)-59.01 (-68.01 to -50.00)-70.00 (-79.19 to -60.81)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -45.64 · 95% CI -59.94 to -31.35Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -34.65 · 95% CI -48.84 to -20.46Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percent Change From Baseline in EASI Score at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · percent change
Adolescents: Percent Change From Baseline in EASI Score at Week 16
percent changeAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percent Change From Baseline in EASI Score at Week 16-43.53 (-51.37 to -35.69)-82.13 (-88.37 to -75.89)-89.42 (-95.82 to -83.02)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -45.89 · 95% CI -55.98 to -35.80Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -38.60 · 95% CI -48.59 to -28.60Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in POEM Total Score at Week 16

The POEM is a 7-item, validated questionnaire used to assess disease symptoms in both children and adults. Participants respond to 7 questions, including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping, each scored on a 5-point scale based on frequency of occurrence during the previous week: 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days. Item scores are added to provide a total score ranging from 0 (clear) to 28 (very severe atopic eczema). A change in POEM score of 3.4 points is considered the minimal clinically important difference.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in POEM Total Score at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in POEM Total Score at Week 1627.3 (15.5 to 39.0)80.6 (70.8 to 90.5)87.9 (79.5 to 96.3)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 60.5 · 95% CI 46.1 to 74.9Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 53.4 · 95% CI 38.2 to 68.7Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in DLQI Score at Week 16

The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in DLQI Score at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in DLQI Score at Week 1633.3 (13.2 to 53.5)81.5 (66.8 to 96.1)79.3 (64.6 to 94.1)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 46.1 · 95% CI 21.1 to 71.0Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 51.5 · 95% CI 28.1 to 74.9Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percent Change From Baseline in SCORAD Score at Week 16

SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · percent change
Adolescents: Percent Change From Baseline in SCORAD Score at Week 16
percent changeAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percent Change From Baseline in SCORAD Score at Week 16-30.90 (-39.39 to -22.40)-65.42 (-71.81 to -59.03)-76.35 (-82.80 to -69.90)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -45.45 · 95% CI -56.11 to -34.80Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -34.53 · 95% CI -45.16 to -23.89Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving HADS-A Score and HADS-D Score of < 8 at Week 16

The HADS is a 14-item questionnaire, with seven items related to anxiety (HADS-A) and seven items related to depression (HADS-D). Each item is scored from 0 to 3; scores for each subscale range from 0 to 21, with higher scores indicating more distress. For each domain, scores 7 or lower are considered normal, 8 to 10 are borderline, and 11 or higher indicate clinical anxiety or depression.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving HADS-A Score and HADS-D Score of < 8 at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving HADS-A Score and HADS-D Score of < 8 at Week 163.8 (0.0 to 11.2)48.6 (32.0 to 65.1)55.6 (36.8 to 74.3)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 51.7 · 95% CI 31.7 to 71.8Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 44.7 · 95% CI 26.7 to 62.8Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16

The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 164.8 (0.0 to 13.9)22.2 (6.5 to 37.9)30.0 (13.6 to 46.4)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = 0.010 · Adjusted response rate difference: 24.9 · 95% CI 6.1 to 43.8Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = 0.090 · Adjusted response rate difference: 16.6 · 95% CI -2.6 to 35.7Response Rate Difference = Upadacitinib - Placebo

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from enrollment to the end of the study. The median time followed ranged from 128.5 days to 133.0 days for the double-blind period and from 1688.0 days to 1711.5 days for the blinded extension period.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adults: Double-blind Period - Placebo0/241 (0%)9/241 (3.7%)111/241 (46.1%)
Adults: Double-blind Period - Upadacitinib 15 mg QD0/239 (0%)5/239 (2.1%)104/239 (43.5%)
Adults: Double-blind Period - Upadacitinib 30 mg QD0/243 (0%)8/243 (3.3%)142/243 (58.4%)
Adolescents: Double-blind Period - Placebo0/61 (0%)1/61 (1.6%)18/61 (29.5%)
Adolescents: Double-blind Period - Upadacitinib 15 mg QD0/64 (0%)2/64 (3.1%)33/64 (51.6%)
Adolescents: Double-blind Period - Upadacitinib 30 mg QD0/64 (0%)0/64 (0%)32/64 (50%)
Adults: Blinded Extension Period - Upadacitinib 15 mg2/231 (0.9%)33/231 (14.3%)160/231 (69.3%)
Adults: Blinded Extension Period - Upadacitinib 30 mg2/228 (0.9%)42/228 (18.4%)189/228 (82.9%)
Adults: Blinded Extension Period - PBO/Upadacitinib 15 mg0/102 (0%)15/102 (14.7%)78/102 (76.5%)
Adults: Blinded Extension Period - PBO/Upadacitinib 30 mg1/105 (1%)21/105 (20%)89/105 (84.8%)
Adolescents: Blinded Extension Period - Upadacitinib 15 mg QD0/64 (0%)8/64 (12.5%)44/64 (68.8%)
Adolescents: Blinded Extension Period - Upadacitinib 30 mg QD0/64 (0%)7/64 (10.9%)48/64 (75%)
Adolescents: Blinded Extension Period - PBO/ Upadacitinib 15 mg0/30 (0%)1/30 (3.3%)20/30 (66.7%)
Adolescents: Blinded Extension Period - PBO/ Upadacitinib 30 mg0/27 (0%)6/27 (22.2%)22/27 (81.5%)
Most frequent serious events
Showing 10 of 158
Most frequent serious events
EventAdults: Double-blind Period - PlaceboAdults: Double-blind Period - Upadacitinib 15 mg QDAdults: Double-blind Period - Upadacitinib 30 mg QDAdolescents: Double-blind Period - PlaceboAdolescents: Double-blind Period - Upadacitinib 15 mg QDAdolescents: Double-blind Period - Upadacitinib 30 mg QDAdults: Blinded Extension Period - Upadacitinib 15 mgAdults: Blinded Extension Period - Upadacitinib 30 mgAdults: Blinded Extension Period - PBO/Upadacitinib 15 mgAdults: Blinded Extension Period - PBO/Upadacitinib 30 mgAdolescents: Blinded Extension Period - Upadacitinib 15 mg QDAdolescents: Blinded Extension Period - Upadacitinib 30 mg QDAdolescents: Blinded Extension Period - PBO/ Upadacitinib 15 mgAdolescents: Blinded Extension Period - PBO/ Upadacitinib 30 mg
TACHYCARDIACardiac disorders0/2410/2390/2430/610/640/640/2310/2280/1020/1050/640/640/301/27
APPENDICITISInfections and infestations0/2411/2390/2430/610/640/640/2311/2281/1020/1050/640/640/301/27
OSTEOMYELITISInfections and infestations0/2410/2390/2430/610/640/640/2311/2280/1020/1050/640/640/301/27
PYELONEPHRITISInfections and infestations0/2410/2390/2430/610/640/640/2310/2280/1021/1050/640/640/301/27
STAPHYLOCOCCAL SEPSISInfections and infestations0/2410/2390/2430/610/640/641/2311/2280/1020/1050/640/640/301/27
RHABDOMYOLYSISMusculoskeletal and connective tissue disorders0/2410/2390/2430/610/640/640/2310/2280/1020/1050/640/640/301/27
DEPRESSIONPsychiatric disorders0/2410/2390/2430/610/640/640/2310/2281/1020/1050/640/640/301/27
PERITONSILLAR ABSCESSInfections and infestations0/2410/2390/2430/610/640/640/2310/2280/1020/1050/640/641/300/27
ECZEMA HERPETICUMInfections and infestations0/2410/2390/2430/610/640/641/2310/2280/1023/1050/640/640/300/27
INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders0/2410/2390/2430/610/640/641/2311/2282/1020/1050/640/640/300/27
Most frequent other events
Showing 10 of 48
Most frequent other events
EventAdults: Double-blind Period - PlaceboAdults: Double-blind Period - Upadacitinib 15 mg QDAdults: Double-blind Period - Upadacitinib 30 mg QDAdolescents: Double-blind Period - PlaceboAdolescents: Double-blind Period - Upadacitinib 15 mg QDAdolescents: Double-blind Period - Upadacitinib 30 mg QDAdults: Blinded Extension Period - Upadacitinib 15 mgAdults: Blinded Extension Period - Upadacitinib 30 mgAdults: Blinded Extension Period - PBO/Upadacitinib 15 mgAdults: Blinded Extension Period - PBO/Upadacitinib 30 mgAdolescents: Blinded Extension Period - Upadacitinib 15 mg QDAdolescents: Blinded Extension Period - Upadacitinib 30 mg QDAdolescents: Blinded Extension Period - PBO/ Upadacitinib 15 mgAdolescents: Blinded Extension Period - PBO/ Upadacitinib 30 mg
COVID-19Infections and infestations0/2410/2391/2430/611/640/6466/23180/22839/10240/10516/6423/646/306/27
ACNESkin and subcutaneous tissue disorders7/24113/23940/2431/619/6410/6425/23143/22814/10224/1051/6418/645/3010/27
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations17/24123/23931/2435/615/648/6435/23135/22819/10214/10514/6418/645/309/27
DERMATITIS ATOPICSkin and subcutaneous tissue disorders20/2419/2395/2432/612/641/6437/23141/22819/10210/1058/646/644/308/27
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations4/24112/23911/2432/615/645/6419/23135/2284/10218/1058/649/645/306/27
NASOPHARYNGITISInfections and infestations16/24119/23928/2431/613/645/6438/23132/22815/10213/1058/648/643/304/27
HERPES ZOSTERInfections and infestations0/2414/2394/2430/611/641/6423/23130/2283/10212/1051/647/642/304/27
IMPETIGOInfections and infestations6/2413/2392/2430/611/641/6411/23112/2282/1024/1055/648/642/302/27
HORDEOLUMInfections and infestations1/2410/2395/2430/611/640/642/23110/2283/1022/1050/641/640/303/27
PHARYNGITISInfections and infestations0/2411/2391/2430/611/641/646/2312/2282/1021/1051/643/642/303/27

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)Adults: PlaceboAdults: Upadacitinib 15 mg QDAdults: Upadacitinib 30 mg QDAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QDTotal
Mean37.6 ± 14.4437.3 ± 14.8036.7 ± 15.1215.1 ± 1.7015.5 ± 1.9915.7 ± 1.6332.7 ± 15.87
Age, Customized
Age, Customized(Participants)Adults: PlaceboAdults: Upadacitinib 15 mg QDAdults: Upadacitinib 30 mg QDAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QDTotal
12 - 14 years00023221560
15 - 17 years000384249129
18 - < 40 years145143154000442
40 - < 65 years858374000242
≥ 65 years11131500039
Sex: Female, Male
Sex: Female, Male(Participants)Adults: PlaceboAdults: Upadacitinib 15 mg QDAdults: Upadacitinib 30 mg QDAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QDTotal
Female114103110333436430
Male127136133283028482
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Adults: PlaceboAdults: Upadacitinib 15 mg QDAdults: Upadacitinib 30 mg QDAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QDTotal
Hispanic or Latino302734101319133
Not Hispanic or Latino211212209515145779
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Adults: PlaceboAdults: Upadacitinib 15 mg QDAdults: Upadacitinib 30 mg QDAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QDTotal
American Indian or Alaska Native1002003
Asian625761101210212
Native Hawaiian or Other Pacific Islander1110003
Black or African American1620766055
White157153163414550609
More than one race481121430
Unknown or Not Reported0000000
Study Enrollment
Study Enrollment(Participants)Adults: PlaceboAdults: Upadacitinib 15 mg QDAdults: Upadacitinib 30 mg QDAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QDTotal
Main Study241239243404242847
Adolescent Substudy (not included in main study)00021222265
Geographic Region
Geographic Region(Participants)Adults: PlaceboAdults: Upadacitinib 15 mg QDAdults: Upadacitinib 30 mg QDAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QDTotal
US/Puerto Rico/Canada108107108313333420
Japan13141411245
China13131511245
Other107105106282927402
vIGA-AD
vIGA-AD(Participants)Adults: PlaceboAdults: Upadacitinib 15 mg QDAdults: Upadacitinib 30 mg QDAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QDTotal
3 (Moderate)132130129353537498
4 (Severe)109109114262927414

2 further baseline measures are reported on the registry.

08

Study locations

180 sites
  • Alliance Dermatology and MOHs /ID# 200375
    Phoenix, Arizona 85032, United States
  • Clear Dermatology & Aesthetics Center /ID# 201256
    Scottsdale, Arizona 85255-4134, United States
  • Bakersfield Derma & Skin Cance /ID# 200433
    Bakersfield, California 93309, United States
  • First OC Dermatology /ID# 201910
    Fountain Valley, California 92708-3701, United States
  • California Allergy and Asthma Medical Group /ID# 200727
    Los Angeles, California 90025-7014, United States
  • Allergy & Asthma Associates of Southern California /ID# 200733
    Mission Viejo, California 92691-6410, United States
  • Dermatology Clinical Trials /ID# 205876
    Newport Beach, California 92660-7853, United States
  • UC Davis /ID# 203622
    Sacramento, California 95817, United States
  • Synergy Dermatology /ID# 200842
    San Francisco, California 94132-1909, United States
  • San Luis Derm and Laser Clinic /ID# 200372
    San Luis Obispo, California 93405, United States
  • Stanford University /ID# 200440
    Stanford, California 94305, United States
  • Care Access Research - Walnut Creek /ID# 200940
    Walnut Creek, California 94598-2488, United States
  • Dermatology Physicians of Connecticut /ID# 200928
    Shelton, Connecticut 06484-6211, United States
  • Foxhall Research Center /ID# 213682
    Washington D.C., District of Columbia 20016-4300, United States
  • Duplicate_George Washington Univ Med /ID# 200364
    Washington D.C., District of Columbia 20037, United States
  • Clearlyderm Dermatology /ID# 208371
    Boca Raton, Florida 33428, United States
  • Skin Care Research, LLC /ID# 200811
    Boca Raton, Florida 33486-2269, United States
  • Olympian Clinical Research /ID# 202914
    Clearwater, Florida 33756, United States
  • Multi-Speciality Research Associates /ID# 213254
    Lake City, Florida 32055-8835, United States
  • GSI Clinical Research, LLC /ID# 200849
    Margate, Florida 33063, United States
  • Florida International Rsrch cr /ID# 218507
    Miami, Florida 33173, United States
  • Tory P Sullivan, MD PA /ID# 200671
    North Miami Beach, Florida 33162-4708, United States
  • Leavitt Medical Associates of Florida /ID# 200880
    Ormond Beach, Florida 32174, United States
  • Precision Clinical Research /ID# 209002
    Sunrise, Florida 33351-7311, United States
  • Integrated Clinical Research LLC /ID# 200900
    West Palm Beach, Florida 33406-6063, United States
  • Christie Clinic, LLC /ID# 200427
    Champaign, Illinois 61820, United States
  • Northwestern University Feinberg School of Medicine /ID# 201644
    Chicago, Illinois 60611-2927, United States
  • Dawes Fretzin, LLC /ID# 200366
    Indianapolis, Indiana 46256, United States
  • The South Bend Clinic Center /ID# 200371
    South Bend, Indiana 46617, United States
  • Clinical Trials Management, LLC - Covington /ID# 212658
    Covington, Louisiana 70433, United States
  • Clinical Trials Management, LLC - Metairie /ID# 212659
    Metairie, Louisiana 70006-4165, United States
  • Northeast Dermatology /ID# 201338
    Beverly, Massachusetts 01915, United States
  • Massachusetts General Hospital /ID# 200474
    Boston, Massachusetts 02114, United States
  • Integrated Dermatology of Massachusetts, LLC /ID# 209468
    Quincy, Massachusetts 02169, United States
  • Clin Res Inst of Michigan, LLC /ID# 208019
    Chesterfield, Michigan 48047, United States
  • Henry Ford Medical Center /ID# 204191
    Detroit, Michigan 48202-3046, United States
  • Cleaver Dermatology /ID# 202825
    Kirksville, Missouri 63501-5362, United States
  • Advanced Dermatology of the Midlands /ID# 201689
    Omaha, Nebraska 68144-1105, United States
  • Clinical Research Consortium /ID# 200734
    Las Vegas, Nevada 89119-5190, United States
  • AllCutis Research Inc /ID# 200981
    Portsmouth, New Hampshire 03801, United States
  • Forest Hills Dermatology Group /ID# 209244
    Kew Gardens, New York 11415, United States
  • Icahn School of Medicine at Mount Sinai /ID# 200370
    New York, New York 10029-6504, United States
  • Montefiore Medical Center /ID# 200456
    The Bronx, New York 10467, United States
  • J. Schwartz, MD, PLLC /ID# 202121
    Troy, New York 12180-2323, United States
  • Velocity clinical research /ID# 202653
    Cleveland, Ohio 44122, United States
  • Lynn Health Science Institute (LHSI) /ID# 212676
    Oklahoma City, Oklahoma 73112, United States
  • Newton Clinical Research /ID# 204169
    Oklahoma City, Oklahoma 73120-5049, United States
  • Oregon Medical Res Center PC /ID# 200428
    Portland, Oregon 97223, United States
  • Oregon Health and Science University /ID# 200992
    Portland, Oregon 97239, United States
  • Dermdox Dermatology Centers, PC /ID# 213782
    Hazleton, Pennsylvania 18201, United States
  • Clinical Partners, LLC /ID# 200460
    Johnston, Rhode Island 02919, United States
  • Coastal Clinical Research Center of the Carolinas /ID# 200402
    Charleston, South Carolina 29414, United States
  • Arlington Research Center, Inc /ID# 200391
    Arlington, Texas 76011, United States
  • Orion Clinical Research /ID# 204703
    Austin, Texas 78759-4100, United States
  • Modern Research Associates, PL /ID# 200705
    Dallas, Texas 75231, United States
  • Menter Dermatology Res Inst /ID# 200390
    Dallas, Texas 75246, United States
  • Center for Clinical Studies - Webster TX /ID# 203185
    Webster, Texas 77598, United States
  • Dermatology Specialists of Spokane /ID# 202068
    Spokane, Washington 99202, United States
  • Framingham Centro Medico /ID# 202688
    La Plata, Buenos Aires 1902, Argentina
  • Instituto de Neumonología y Dermatología /ID# 203444
    Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma de Buenos Aires 1425, Argentina
  • Psoriahue Med Interdisciplinar /ID# 202451
    Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma de Buenos Aires 1425, Argentina
  • Woden Dermatology /ID# 205799
    Phillip, Australian Capital Territory 2606, Australia
  • Holdsworth House Medical Practice /ID# 211236
    Darlinghurst, New South Wales 2010, Australia
  • North Eastern Health Specialists /ID# 205802
    Hectorville, South Australia 5073, Australia
  • Skin Health Institute Inc /ID# 204791
    Carlton, Victoria 3053, Australia
  • Fremantle Dermatology /ID# 205305
    Fremantle, Western Australia 6160, Australia
  • University Clinical Centre of the Republic of Srpska /ID# 202666
    Banja Luka, Republika Srpska 78000, Bosnia and Herzegovina
  • University Clinical Centre of the Republic of Srpska /ID# 202667
    Banja Luka, Republika Srpska 78000, Bosnia and Herzegovina
  • Clinical Center University of Sarajevo /ID# 202668
    Sarajevo, 71000, Bosnia and Herzegovina
  • Clinical Center University of Sarajevo /ID# 202669
    Sarajevo, 71000, Bosnia and Herzegovina
  • UMHAT Dr Georgi Stranski EAD /ID# 201521
    Pleven, 5800, Bulgaria
  • UMHAT Alexandrovska EAD /ID# 201519
    Sofia, 1431, Bulgaria
  • UMHAT Professor Stoyan Kirkovich /ID# 201522
    Stara Zagora, 6000, Bulgaria
  • Kirk Barber Research, CA /ID# 200324
    Calgary, Alberta T2G 1B1, Canada
  • Dermatology Research Institute Inc. /ID# 200318
    Calgary, Alberta T2J 7E1, Canada
  • Dr. Chih-ho Hong Medical Inc. /ID# 200311
    Surrey, British Columbia V3R 6A7, Canada
  • Enverus Medical Research /ID# 200307
    Surrey, British Columbia V3V 0C6, Canada
  • Wiseman Dermatology Research /ID# 200323
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Dr. Irina Turchin PC Inc. /ID# 200322
    Fredericton, New Brunswick E3B 1G9, Canada
  • Karma Clinical Trials /ID# 200316
    St. John's, Newfoundland and Labrador A1A 4Y3, Canada
  • Hamilton Health Sciences - McMaster University Medical Centre /ID# 200313
    Hamilton, Ontario L8S 4K1, Canada
  • Dr. Wei Jing Loo Medicine Prof /ID# 206051
    London, Ontario N6H 5L5, Canada
  • Lynderm Research Inc. /ID# 200315
    Markham, Ontario L3P 1X2, Canada
  • Dermatology Ottawa Research Centre /ID# 200319
    Ottawa, Ontario K2C 3N2, Canada
  • K. Papp Clinical Research /ID# 200317
    Waterloo, Ontario N2J 1C4, Canada
  • Innovaderm Research Inc. /ID# 200320
    Montreal, Quebec H2X 2V1, Canada
  • Dr. David Gratton Dermat Inc. /ID# 200309
    Montreal, Quebec H3H 1V4, Canada
  • Dre Angelique Gagne-Henley M.D. inc. /ID# 200326
    Saint-Jérôme, Quebec J7Z 7E2, Canada
  • Peking University People's Hospital /ID# 202549
    Beijing, Beijing Municipality 100044, China
  • Peking University Third Hospital /ID# 202612
    Beijing, Beijing Municipality 100191, China
  • Sun Yat-sen Memorial Hospital of Sun Yat-sen University /ID# 208597
    Guangzhou, Guangdong 510120, China
  • The Third Affiliated Hospital Of Sun Yat-Sen University /ID# 202548
    Guangzhou, Guangdong 510630, China
  • The First Hospital of China Medical University /ID# 202615
    Shenyang, Liaoning 110001, China
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 202554
    Shanghai, Shanghai Municipality 200065, China
  • The second Affiliated hospital of Zhejiang University school of Medicine /ID# 202608
    Hangzhou, Zhejiang 310009, China
  • Beijing Friendship Hospital /ID# 202601
    Beijing, 100032, China
  • Huashan Hospital of Fudan University /ID# 205760
    Shanghai, 200040, China
  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 208598
    Wuhan, 420022, China
  • Clinisalud del sur /ID# 218100
    Medellín, Antioquia 055422, Colombia
  • Fundacion Hospital San Vicente de Paul - Rionegro /ID# 202043
    Rionegro, Antioquia 054040, Colombia

Showing the first 100 of 180 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Silverberg JI, Prajapati VH, Abraham S, Irvine AD, Gooderham MJ, Guttman-Yassky E, Tanizaki H, Rademaker M, Chen SH, Moreira A, Ta R, Lee WJ, Eyerich K. Achieving Minimal Disease Activity in Atopic Dermatitis Is Associated with Fewer Flares, Reduced Healthcare Resource Utilization, and Improved Disease Control: Analysis from the Real-World MEASURE-AD Study. Dermatol Ther (Heidelb). 2026 Jul 30. doi: 10.1007/s13555-026-01865-0. Online ahead of print. PubMed 42530735 ↗
  • Eyerich K, Mendes-Bastos P, Holzer G, Jain V, Katoh N, Luna PC, Segura PC, Lane M, Grada A, Moreira A, Bunick CG. Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region. Dermatol Ther (Heidelb). 2026 Jul;16(7):3461-3477. doi: 10.1007/s13555-026-01793-z. Epub 2026 May 24. PubMed 42177735 ↗
  • Irvine AD, Prajapati VH, Guttman-Yassky E, Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Gold LFS, de Bruin-Weller M, Bieber T, Kabashima K, Rosmarin D, Sancho C, Calimlim BM, Grada A, Yang Y, Wu X, Levy G, Raymundo EM, Teixeira HD, Silverberg JI. Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks. Am J Clin Dermatol. 2025 Nov;26(6):1003-1016. doi: 10.1007/s40257-025-00975-3. Epub 2025 Sep 3. PubMed 40900410 ↗
  • Burmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, Levy G, Suravaram S, Palac H, Wegrzyn L, Ford S, Meerwein S, Guttman-Yassky E. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. Adv Ther. 2025 Oct;42(10):5215-5237. doi: 10.1007/s12325-025-03328-y. Epub 2025 Aug 28. PubMed 40875187 ↗
  • Simpson EL, Silverberg JI, Prajapati VH, Eyerich K, Katoh N, Boguniewicz M, Guttman-Yassky E, Song EJ, Lee WJ, Teixeira HD, Wu T, Sancho Sanchez C, Vigna N, Calimlim BM, de Bruin-Weller M. Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis. Dermatol Ther (Heidelb). 2025 Aug;15(8):2061-2076. doi: 10.1007/s13555-025-01443-w. Epub 2025 Jun 2. PubMed 40457140 ↗
  • Paller AS, Mendes-Bastos P, Siegfried E, Eichenfield LF, Soong W, Prajapati VH, Lio P, Simpson EL, Raymundo EM, Suravaram S, Hu X, Yang Y, Huang X, Calimlim BM, Platt AM, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks. JAMA Dermatol. 2024 Dec 1;160(12):1304-1313. doi: 10.1001/jamadermatol.2024.3696. PubMed 39441580 ↗
  • Blauvelt A, Eyerich K, Irvine AD, de Bruin-Weller M, Kwatra SG, Gooderham M, Kim B, Calimlim BM, Lee WJ, Raymundo EM, Liu Y, Ofori S, Platt AM, Silverberg JI. More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis. Dermatol Ther (Heidelb). 2024 Sep;14(9):2621-2630. doi: 10.1007/s13555-024-01242-9. Epub 2024 Aug 7. PubMed 39110139 ↗
  • Simpson EL, Prajapati VH, Leshem YA, Chovatiya R, de Bruin-Weller MS, Stander S, Pink AE, Calimlim BM, Lee WJ, Teixeira H, Ladizinski B, Hu X, Yang Y, Liu Y, Liu M, Grada A, Platt AM, Silverberg JI. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2). Dermatol Ther (Heidelb). 2024 May;14(5):1127-1144. doi: 10.1007/s13555-024-01157-5. Epub 2024 May 2. PubMed 38696027 ↗
  • Silverberg JI, Gooderham MJ, Paller AS, Deleuran M, Bunick CG, Gold LFS, Hijnen D, Calimlim BM, Lee WJ, Teixeira HD, Hu X, Zhang S, Yang Y, Grada A, Platt AM, Thaci D. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2). Am J Clin Dermatol. 2024 May;25(3):485-496. doi: 10.1007/s40257-024-00853-4. Epub 2024 Mar 25. PubMed 38528257 ↗
  • Thyssen JP, Thaci D, Bieber T, Gooderham M, de Bruin-Weller M, Soong W, Kabashima K, Barbarot S, Luna PC, Xu J, Hu X, Liu Y, Raymundo EM, Calimlim BM, Nduaka C, Gamelli A, Simpson EL. Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1871-1880. doi: 10.1111/jdv.19232. Epub 2023 Jun 21. PubMed 37247226 ↗
  • Paller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH, Lio P, Thyssen JP, Simpson EL, Platt AM, Raymundo EM, Liu J, Calimlim BM, Huang X, Gu Y, Hu X, Yang Y, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials. JAMA Dermatol. 2023 May 1;159(5):526-535. doi: 10.1001/jamadermatol.2023.0391. PubMed 37043227 ↗
  • Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023 Feb;9(1):e002735. doi: 10.1136/rmdopen-2022-002735. PubMed 36754548 ↗
  • Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, Jiang P, Liu J, Prajapati VH, Simpson EL, Vigna N, Teixeira HD, Barbarot S. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022 Oct;87(4):784-791. doi: 10.1016/j.jaad.2022.06.012. Epub 2022 Jun 15. PubMed 35714786 ↗
  • Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N, Calimlim BM, Thyssen JP, Chiou AS, Bissonnette R, Stein Gold LF, Wegzyn C, Hu X, Liu M, Liu J, Tenorio AR, Chu AD, Guttman-Yassky E. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials. JAMA Dermatol. 2022 Apr 1;158(4):404-413. doi: 10.1001/jamadermatol.2022.0029. PubMed 35262646 ↗
  • Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, Thaci D, Chu CY, Hong HC, Katoh N, Paller AS, Calimlim B, Gu Y, Hu X, Liu M, Yang Y, Liu J, Tenorio AR, Chu AD, Irvine AD. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021 Jun 5;397(10290):2151-2168. doi: 10.1016/S0140-6736(21)00588-2. Epub 2021 May 21. PubMed 34023008 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Jan 2021, 28 months.

Results were first posted in Feb 2022, 1 year after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 28 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2018
First posted
Jun 26, 2018
StartActual
Aug 13, 2018
Primary completionActual
Jan 6, 2021
CompletionActual
Oct 10, 2025
Results first posted
Feb 3, 2022
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03569293
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 26, 2018
Start date
Aug 13, 2018
Primary completion
Jan 6, 2021
Completion
Oct 10, 2025
Results posted
Feb 3, 2022
Last update
Jun 17, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion